Miniatura

Fitxers

s41467-025-57284-w.pdf (3.04 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-03-04

Llicència de publicació

cc-by-nc-nd (c) Bailón et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/221361

Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41467-025-57284-w

Resum

Building on results from the AELIX-002 trial with HIVACAT T-cell immunogen (HTI)-based vaccines, the AELIX-003 (NCT04364035) trial tested the safety of the combination of ChAdOx1.HTI (C) and MVA.HTI (M), with the TLR7 agonist vesatolimod (VES), in a double-blind, placebo-controlled, randomized clinical trial in 50 virally suppressed early-treated men with HIV-1 infection. Secondary objectives included immunogenicity and effects on viral rebound kinetics during a 24-week antiretroviral treatment interruption (ATI). The most common treatment-related adverse events were mild-to-moderate injection-site pain, influenza-like illness, headache, and fatigue. Strong, broad, and HTI-focused T-cell responses were induced by vaccination. All participants experienced viral rebound in ATI; 33.3% and 23.5% (P = 0.4494) of CCMM + VES and placebo recipients, respectively, remained off antiretroviral therapy for 24 weeks. Post hoc analysis confirmed a correlation between levels of HTI-specific T cells and prolonged time off antiretroviral therapy. The combination of HTI vaccines and VES was safe and elicited robust T-cell responses.

Matèries

Antiretrovirals, VIH (Virus), Assaigs clínics

Matèries (anglès)

Antiretroviral agents, HIV (Viruses), Clinical trials

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

BAILÓN, Lucia, MOLTÓ, José, CURRAN, Adrian, CADIÑANOS LOIDI, Julen, LÓPEZ BERNALDO DE QUIRÓS, Juan carlos, SANTOS, Ignacio de los, AMBROSIONI, Juan, IMAZ, Arkaitz, BENET, Susana, SUANZES, Paula, NAVARRO, Jordi, GONZÁLEZ GARCÍA, Juan, BUSCA, Carmen, PÉREZ LATORRE, Leire, BERENGUER, Juan, GARCÍA FRAILE FRAILE, Lucio jesús, MEJÍA ABRIL, Gina, MIRÓ MEDA, José m. (josé maría), SCÉVOLA, Sofía, MORENO GUILLÉN, Santiago, DOMINGO, Pere (domingo pedrol), TIAN, Yuan, FRANKOT, Michelle, LIM, Daina, CAI, Yanhui, VENDRAME, Elena, GUO, Susan, WALLIN, Jeffrey j., GELEZIUNAS, Romas, SENGUPTA, Devi, ALARCÓN SOTO, Yovaninna, LEAL CORTIJO, Isabel, ARANGUEN IBÁÑEZ, Alvaro, GARCÍA GARCÍA, Margarida, MCGOWAN, Ian, BRANDER, Christian, ARRIBAS, Jose ramón, MOTHE, Beatriz, The Aelix-003 Study Group. Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial. _Nature Communications_. 2025. Vol. 16. [consulta: 27 de febrer de 2026]. ISSN: 2041-1723. [Disponible a: https://hdl.handle.net/2445/221361]

Exportar metadades

JSON - METS

Compartir registre